

Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Moxifloxacin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

117 16th Road

1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Additional Labelling

EUH210 Safety data sheet available on request.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 0,1 - <= 0,2

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

No hazardous combustion products are known

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.



Moxifloxacin Liquid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 28.09.2024 1731712-00014 Date of first issue: 05.06.2017 1.13

Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Use only with adequate ventilation. Advice on safe handling

Avoid inhalation of vapour or mist.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Do not store with the following product types: Advice on common storage

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) No data available



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Moxifloxacin HCL	186826-86- 8	TWA	1000 μg/m3 (OEB 1)	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : liquid
Colour : yellow
Odour : odourless

Odour Threshold : No data available

pH : 4,1 - 4,6

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1,0044 g/cm³ (20 °C)

Solubility(ies)

Water solubility : slightly soluble Partition coefficient: n- : No data available

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Acute oral toxicity : LD50 (Rat): 1.320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1.500 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Monkey Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.13 28.09.2024 1731712-00014 Date of first issue: 05.06.2017

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Moxifloxacin HCL:

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species : Rat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat

NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Species : Rat
NOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : Liver

Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Symptoms : No adverse effects

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 1.13 28.09.2024 1731712-00014 Date of first issue: 05.06.2017

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

Acute Tox. : Acute toxicity Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-



Moxifloxacin Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 1.13
 28.09.2024
 1731712-00014
 Date of first issue: 05.06.2017

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN